On May 8, 2023 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported the Company’s participation in the following upcoming industry and investor conferences to be held in May 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event: Sidoti Micro Cap Conference
Conference Dates: May 10 – 11, 2023
Virtual Presentation: Thursday, May 11 at 12:15 p.m. ET in Track 3
Virtual Presentation Link: https://bit.ly/3APq2xY
Presenter: Ryan Confer, Chief Financial Officer
Mr. Confer will deliver an overview of the Company’s pioneering gene therapies for cancer and diabetes and will be available for virtual one-on-one meetings with investors through the Sidoti conference platform.
A recording of this presentation will be available for replay on Genprex’s website for a period of time.
Event: American Society of Gene & Cell Therapy Annual Meeting
Conference Dates: May 16 – 20, 2023
Genprex’s Chief Technology and Manufacturing Officer, Hemant Kumar, PhD, and Senior Vice Preisdent of Intellectual Property and Licensing, Thomas Gallagher, will participate in the ASGCT (Free ASGCT Whitepaper) annual meeting. Both Dr. Kumar and Mr. Gallagher will be available for in-person meetings with conference attendees.
Event: A.G.P.’s Virtual Healthcare Conference
Conference Date: May 23 – 24, 2023
Several members of the Genprex management team will participate in the A.G.P. Virtual Healthcare Conference.
For those interested in meeting Genprex management during these conferences, please request a meeting through the conference portals or reach out to Investor Relations at [email protected].